Page 6 - Wockhardt

Market Wrap, Feb 13: Sensex slips 106 pts, Nifty ends at 12,175

Sectorally, Nifty Private Bank index fell around 1.4 per cent to 17,083 levels. Nifty Bank slid 0.8 per cent to 31,230 points. On the upside, pharma and IT stocks advanced the most

Wockhardt tanks 5% after it sells domestic branded ops to Dr Reddy's Labs

The deal, which could fetch a consideration amount of Rs 1,850 crore, is expected to close in the first quarter of financial year 2020-21, Wockhardt added.

Wockhardt sells part of branded biz to Dr Reddy's for Rs 1850 crore

Deal would help Wockhardt focus on international operations, novel pipeline R&D

Dr Reddy's to acquire part of Wockhardt's India business for Rs 1,850 crore

The agreement comprises a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, and dermatology.

Market Wrap, Feb 11: Sensex snaps 2-day losing streak, rises 237 pts

In the intra-day deals, the Sensex and Nifty50 hit a high of 41,444.34 and 12,172.30 level, respectively

Wockhardt hits over 7-month high; stock zooms 63% in one month

The stock was trading higher for the third straight day, surging 10 per cent, on the BSE on Tuesday. It was its highest level since June 27, 2019.

Wockhardt becomes first Indian company to get nod for novel antibiotics

While multinational companies have launched new antibiotics in India, there have been no new launches in the past 15 years in this category

Top headlines: SC dismisses AGR review petitions, ED summons AirAsia execs

The Enforcement Directorate (ED) has summoned senior executives of AirAsia including CEO Tony Fernandes for questioning in connection with a money laundering case

Wockhardt consolidated net loss narrows to Rs 45 cr for June 2019 quarter

Total income of the company stood at Rs 871.19 crore during the quarter under review

Wockhardt's shares plunge 7% after Q3 net loss widens to Rs 71.11 crore

Wockhardt had posted a net loss of Rs 40.76 crore for the corresponding period of 2017-18

Wockhardt Q2 net loss widens to Rs 230 million; sales at Rs 11.25 bn

India business stood at Rs 4.55 billion in the quarter as against Rs 4.52 billion in same period last year

Wockhardt up 13% after falling 33% in six weeks

The stock moved higher by 13% to Rs 503 on the BSE in intra-day trade on Monday, after hitting four-year low of Rs 437 on Friday.

HC allows Wockhardt to sell its anti-inflammatory drug till September 18

Ace Proxyvon, which is sold by the company in a tablet form, is a mixture of three salts -- aceclofenac, paracetamol and rabeprazol -- a combination which is banned

Wockhardt Q1 net loss narrows to Rs 860 mn from Rs 4.1 bn a year ago

India, US and Irish business of the company grew by 30 per cent, 20 per cent and 7 per cent respectively

Full recovery for US sales would be possible only by 2020: Wockhardt chief

Complex drugs will be less competitive than vanilla generic, but it is still going to be competitive as global players are there, says Habil Khorakiwala

Investors cheer Wockhardt on revival hopes; stock gained 41% in 2017

The drugmaker lost over Rs 20 billion of sales from the US market over the past four years

Wockhardt settles with Teva and its affiliate in London High Court

This was in relation to a supply contract for a drug named Trisenox

Wockhardt gets shareholders' nod for raising Rs 1,000 cr via QIP route

Drug firm mulling alternatives, including issuing securities to investors

Wockhardt looks for greener pastures as US FDA issues linger

Reported a Rs 196-crore net loss for 2016-17 against a profit of Rs 251 crore in the previous year

Wockhardt seeks shareholders' nod to raise up to Rs 1,000 crore

Shares of the company were trading 0.96% down at Rs 678.45 on BSE